JP2002535367A - 急性心筋梗塞の処置のためのアンギオテンシンｉｉレセプターアンタゴニストの使用 - Google Patents

急性心筋梗塞の処置のためのアンギオテンシンｉｉレセプターアンタゴニストの使用

Info

Publication number
JP2002535367A
JP2002535367A JP2000595681A JP2000595681A JP2002535367A JP 2002535367 A JP2002535367 A JP 2002535367A JP 2000595681 A JP2000595681 A JP 2000595681A JP 2000595681 A JP2000595681 A JP 2000595681A JP 2002535367 A JP2002535367 A JP 2002535367A
Authority
JP
Japan
Prior art keywords
acute
treatment
angiotensin
pharmaceutically acceptable
receptor antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000595681A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002535367A5 (enExample
Inventor
イェシカ・エム・マン
パスカル・オドゥ
エリック・ミシェル・ヌアール
Original Assignee
ノバルティス アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26153740&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2002535367(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アクチエンゲゼルシャフト filed Critical ノバルティス アクチエンゲゼルシャフト
Publication of JP2002535367A publication Critical patent/JP2002535367A/ja
Publication of JP2002535367A5 publication Critical patent/JP2002535367A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2000595681A 1999-01-26 2000-01-24 急性心筋梗塞の処置のためのアンギオテンシンｉｉレセプターアンタゴニストの使用 Withdrawn JP2002535367A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP99810061 1999-01-26
US46866499A 1999-12-21 1999-12-21
US09/468,664 1999-12-21
US99810061.4 1999-12-21
PCT/EP2000/000525 WO2000044378A1 (en) 1999-01-26 2000-01-24 Use of angiotensin ii receptor antagonists for treating acute myocardial infarction

Publications (2)

Publication Number Publication Date
JP2002535367A true JP2002535367A (ja) 2002-10-22
JP2002535367A5 JP2002535367A5 (enExample) 2007-02-15

Family

ID=26153740

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000595681A Withdrawn JP2002535367A (ja) 1999-01-26 2000-01-24 急性心筋梗塞の処置のためのアンギオテンシンｉｉレセプターアンタゴニストの使用

Country Status (25)

Country Link
EP (2) EP1714651A1 (enExample)
JP (1) JP2002535367A (enExample)
KR (1) KR100674053B1 (enExample)
CN (1) CN1337879A (enExample)
AT (1) ATE330599T1 (enExample)
AU (1) AU766453C (enExample)
BR (1) BR0007686A (enExample)
CA (1) CA2360691A1 (enExample)
CY (1) CY1105257T1 (enExample)
CZ (1) CZ20012682A3 (enExample)
DE (1) DE60028928T2 (enExample)
DK (1) DK1146872T3 (enExample)
ES (1) ES2265910T3 (enExample)
HK (1) HK1041808B (enExample)
HU (1) HUP0105199A3 (enExample)
ID (1) ID29818A (enExample)
IL (2) IL144216A0 (enExample)
NO (1) NO20013459L (enExample)
NZ (1) NZ513039A (enExample)
PL (1) PL197161B1 (enExample)
PT (1) PT1146872E (enExample)
RU (2) RU2298405C2 (enExample)
SI (1) SI1146872T1 (enExample)
SK (1) SK10522001A3 (enExample)
WO (1) WO2000044378A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100646716B1 (ko) 1998-12-23 2006-11-17 노파르티스 아게 Ａｔ-1 또는 ａｔ-2 수용체의 증가와 관련된 질환의치료에 있어서 ａｔ-1 수용체 길항제 또는 ａｔ-2 수용체조절제의 용도
AU2001284413A1 (en) * 2000-08-30 2002-03-13 Sankyo Company Limited Medicinal compositions for preventing or treating heart failure
US7076287B2 (en) 2000-12-29 2006-07-11 Ge Medical Systems Information Technologies, Inc. System and method for detecting new left bundle branch block for accelerating treatment of acute myocardial infarction
US20040266836A1 (en) * 2001-10-18 2004-12-30 Peter Buhlmayer Organic compounds
WO2003097099A1 (en) * 2002-05-17 2003-11-27 Novartis Ag Combination of angiotensin ii receptor blocker and beta-blocker for secondary prevention of myocardial infarction
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
SE0302331D0 (sv) * 2003-08-29 2003-08-29 Astrazeneca Ab New use II
WO2005030202A1 (en) * 2003-09-26 2005-04-07 Novartis Ag Use of angiotensin ii receptor antagonists for treating cerebrovascular disorders
WO2005053687A1 (en) * 2003-11-25 2005-06-16 Novartis Ag Combination of organic compounds
WO2009087116A1 (en) * 2008-01-11 2009-07-16 Novartis Ag Use of spp100 for the treatment of acute mi
CN104086623B (zh) * 2014-07-02 2017-05-24 牡丹江友搏药业有限责任公司 一种新的具有降压和细胞保护作用的化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027208D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
EP0577025A3 (de) * 1992-07-01 1998-02-04 Hoechst Aktiengesellschaft Angiotensin-II-Rezeptorantagonisten zur Behandlung und Prophylaxe von koronaren Herzerkrankungen
FR2716882B1 (fr) * 1994-03-04 1996-04-05 Roussel Uclaf Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
FR2716883B1 (fr) * 1994-03-04 1996-04-26 Roussel Uclaf Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant.
DE4432860A1 (de) * 1994-09-15 1996-03-21 Merck Patent Gmbh Imidazopyridine
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US5795904A (en) * 1996-12-06 1998-08-18 Merck & Co., Inc. Enhanced functional recovery of the heart by losartan treatment after an ischemic attach

Also Published As

Publication number Publication date
ATE330599T1 (de) 2006-07-15
SI1146872T1 (sl) 2006-12-31
EP1714651A1 (en) 2006-10-25
IL144216A (en) 2007-07-04
RU2006135205A (ru) 2008-04-10
KR20020002379A (ko) 2002-01-09
WO2000044378A1 (en) 2000-08-03
NO20013459D0 (no) 2001-07-12
SK10522001A3 (sk) 2001-12-03
AU766453C (en) 2004-11-25
NO20013459L (no) 2001-09-05
AU2439700A (en) 2000-08-18
EP1146872A1 (en) 2001-10-24
ID29818A (id) 2001-10-11
EP1146872B1 (en) 2006-06-21
DE60028928T2 (de) 2007-01-04
ES2265910T3 (es) 2007-03-01
DE60028928D1 (de) 2006-08-03
RU2345790C2 (ru) 2009-02-10
PT1146872E (pt) 2006-10-31
DK1146872T3 (da) 2006-10-16
AU766453B2 (en) 2003-10-16
HK1041808A1 (en) 2002-07-26
HUP0105199A3 (en) 2004-11-29
NZ513039A (en) 2003-11-28
HUP0105199A2 (hu) 2002-04-29
CZ20012682A3 (cs) 2001-10-17
BR0007686A (pt) 2001-11-06
KR100674053B1 (ko) 2007-01-25
PL197161B1 (pl) 2008-03-31
HK1041808B (en) 2007-01-19
CY1105257T1 (el) 2010-03-03
CA2360691A1 (en) 2000-08-03
CN1337879A (zh) 2002-02-27
IL144216A0 (en) 2002-05-23
RU2298405C2 (ru) 2007-05-10

Similar Documents

Publication Publication Date Title
RU2298418C2 (ru) Комбинация по меньшей мере двух соединений, выбранных из групп антагонистов at1-рецептора или ингибиторов асе (ангиотензинпревращающий фермент), или ингибиторов hmg-coa-редуктазы (бета-гидрокси-бета-метилглутарил-кофермент-а-редуктаза)
PT1467728E (pt) Composições farmacêuticas compreendendo valsartan e inibidores da nep
JP5968927B2 (ja) 高血圧と代謝症候群の治療に用いられる薬物組成物及びその応用
AU766453C (en) Use of angiotensin II receptor antagonists for treating acute myocardial infarction
US6544968B2 (en) Use of angiotensin II receptor antagonists for treating acute myocardial infarction
JP2002535367A5 (enExample)
HK1100021A (en) Use of angiotensin ii receptor antagonists for treating acute myocardial infarction
JP2005531558A (ja) 心筋梗塞の二次予防のためのアンギオテンシンＩＩ受容体ブロッカーおよびβブロッカーの組合せ
WO2005053687A1 (en) Combination of organic compounds
BR112014007876B1 (pt) Forma de dosagem, composição, processo para preparação de uma composição, uso de uma composição
Isenovic et al. O-37: Effect of vasopeptidase inhibition BMS189921 on PI3-kinase signaling in VSMCs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061220

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090907